FindTrial
Sign In

ASP0113

BIOLOGICAL4 trials

Sponsors

Astellas Pharma Global Development, Inc., Astellas Pharma Inc

Conditions

Allogeneic Hematopoietic Cell TransplantAllogeneic, Hematopoietic Cell Transplant (HCT)Cytomegalovirus (CMV)-Positive RecipientsCytomegalovirus InfectionDialysisHealthy SubjectsKidney Transplantation Cytomegalovirus (CMV) Negative Recipients

Phase 1

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
CompletedNCT02103426
Astellas Pharma Global Development, Inc.Cytomegalovirus Infection, Dialysis, Healthy Subjects
Start: 2013-12-30End: 2016-05-10Updated: 2024-10-17

Phase 2

A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
CompletedNCT01903928
Astellas Pharma IncAllogeneic Hematopoietic Cell Transplant
Start: 2013-06-20End: 2015-01-19Updated: 2024-10-17
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
CompletedNCT01974206
Astellas Pharma Global Development, Inc.Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Start: 2013-11-20End: 2020-11-05Updated: 2024-10-24

Phase 3

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
CompletedNCT01877655
Astellas Pharma Global Development, Inc.Allogeneic, Hematopoietic Cell Transplant (HCT), Cytomegalovirus (CMV)-Positive Recipients
Start: 2013-09-11End: 2022-03-01Updated: 2024-10-24

Related Papers

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.
2021-03-1925 citations
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor
American Journal of Transplantation2018-05-1057 citations
Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.
2016-10-2817 citations